GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Deferred Policy Acquisition Costs

Armata Pharmaceuticals (FRA:TG1N) Deferred Policy Acquisition Costs


View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Armata Pharmaceuticals Business Description

Traded in Other Exchanges
Address
5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.